

Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs

 Kumsal Kocadal,¹  Sahan Saygi,¹  Fehmi Burak Alkas,¹  Semra Sardas²

¹Department of Toxicology, Near East University Faculty of Pharmacy, Nicosia, TRNC

²Department of Toxicology, Istinye University Faculty of Pharmacy, Istanbul, Turkey

ABSTRACT

A considerable number of drugs were withdrawn from the world market in the last decades due to safety reasons. A retrospective review of withdrawals is important in determining the adequacy of regulations regarding safety and efficacy of drugs. The scope of this study was to focus on cardiovascular adverse reactions of 61 withdrawn medicinal products, as well as 40 additional drugs withdrawn due to non-cardiovascular toxicity, while being cardiovascular agents themselves. A detailed web-based data search was held to draw a list of withdrawn pharmaceutical products from the pharmaceutical market by regulatory authorities between 1950 and 2017 due to safety reasons. A total 464 medicinal products were withdrawn from the pharmaceutical markets between 1950 and 2017 due to safety reasons. Hepatotoxicity was the most commonly reported adverse drug reaction (ADR) that led to withdrawal followed by immune-related reactions, neurotoxicity and cardiovascular toxicity. The underlying mechanisms leading to cardiovascular toxicity should be investigated in depth to avoid the use of risky drugs for long periods of time, especially in consideration of the fact that some cardiovascular drugs persisted in the market for many decades. Furthermore, improved reporting of suspected adverse reactions and stricter regulations will lead to quicker detection of ADRs, thus emphasising the importance of this public health problem and highlighting the need for improved "early warning systems" to manage the risks of high-risk drugs.

Keywords: Cardiovascular toxicity; drug safety; drug withdrawal.

Cite this article as: Kocadal K., Saygi S., Alkas F. B., Sardas S. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs. *North Clin Istanbul*

A newly designed drug passes through a long and tough route before reaching the market, and throughout its way, the safety, efficacy and quality are the most compellable issues. Although the drugs are tested very elaborately for their safety besides their efficacy during preclinical and clinical trials, some concerns such as difficulties in extrapolating drug data from animal to man, sample size that is required to emphasise to assess clinical benefit, limited duration in relatively healthy adults, detection of rare adverse drug reactions (ADRs) and drug interactions remain as problems to overcome. During pre-clinical and clinical studies, as well as post-marketing surveillance, the drug must satisfy all

safety and efficacy concerns to launch and remain in the pharmaceutical market. These concerns are addressed by the system of pharmacovigilance, the partners of which are health authorities, hospitals, academia, healthcare professionals, pharmaceutical industry and patients. As case-in-point, a meta-analysis published by Lazarou et al. reported that ADRs were responsible for over 100,000 deaths and 2 million hospital admissions, making them between the fourth to sixth commonest causes of death [1]. This prevalence of ADR-related problems also revealed the requirement for national pharmacovigilance systems in the last decades. Although the pharmacovigilance data collected in developed countries initially

Received: February 02, 2018 *Accepted:* April 07, 2018 *Online:* September 05, 2018



Correspondence: Dr. Sahan SAYGI. Yakın Dogu Üniversitesi Eczacılık Fakültesi, Toksikoloji Anabilim Dalı, Yakın Dogu Bulvarı, Pk: 99138 / 99138 Lefkosa, K.K.T.C.

Tel: +90 392 223 64 64 - 5108 e-mail: sahan.saygi@neu.edu.tr

© Copyright 2018 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com

seemed appropriate for extrapolation to other countries, the role of many confounding factors, primarily cultural and genetic predisposition has proven the fallacy of this practice.

Therefore, World Health Organisation (WHO) recommends every country to establish their own pharmacovigilance systems and become full members of the WHO Programme for International Drug Monitoring. As of September 2017, this programme has 127 participating member countries and further 29 countries are associate members whose national pharmacovigilance centres are under establishment [2].

Despite the establishment of Turkish regulatory system in 1985, and membership in the WHO Programme for International Drug Monitoring since 1987, effective oversight and monitoring commenced in 2005 with the establishment of Turkish Pharmacovigilance Centre (TUFAM), which became responsible for detecting post-marketing drug safety problems [3].

In this study, particular emphasis was placed on cardiovascular ADRs due to a multitude of concerns; because of being among the potentially life-threatening conditions and, due to their wide prevalence, being the fourth reason for withdrawal ($n=61$), after hepatotoxicity ($n=81$), immune-related reactions ($n=79$) and neurotoxicity ($n=76$). Moreover, the treatment options for negative cardiovascular effects are either lifelong or cured with major surgery, which both impart a severe medical, psychological and economic burden on the patient, as well as additional costs on the healthcare system [4, 5].

Therefore, the objective of this study was to evaluate drugs withdrawn due to their cardiovascular risks, as well as cardiovascular drugs that were removed from the pharmaceutical market due to adverse effects either related or unrelated to their own pharmacological action all over the globe between the period of 1950 and 2017.

Methods

In the course of this study, a detailed web-based data search and concurrent systematic reviews that summarise all removed drugs from all over the globe have been conducted [4, 6, 7] using the reputable sources given below to compile a list of withdrawn cardiovascular drugs and drugs withdrawn for their cardiovascular concerns. Taking the above statement into account, our review updates and evaluates the data on drugs related to cardiovascular system.

- WHO's Drug Information (Volumes 1–30)
- The WHO's Pharmaceutical Newsletters (1997–2017)
- The UK Medicine and Healthcare Products Regulatory Agency website
- The UK Medicine and Healthcare Products Regulatory Agency, Drug Safety Monthly Updates (January 2015–May 2017)
- The US Food and Drug Administration (FDA) website
- PubMed
- Records of Turkish Medicines and Medical Devices Agency (TMMDA)
- European Medicines Agency (EMA) website

Veterinary medicines and drugs removed due to commercial reasons by pharmaceutical companies were not included in our data.

Results

The sum of the withdrawn drugs adds up to 464 from 88 different pharmacological classes by 2017 according to our recent research. Among the withdrawn drugs, 53 had cardiovascular indications (Table 1), belonging to 11 different pharmacological classes, namely antihypertensives, vasodilator, antilipidemics, antianginals, antiarrhythmics, antithrombotics, anticholesterol agents, cardiac stimulants, thrombolytics, vasopressors, and prostaglandins as demonstrated in Figure 1.

In addition, a total 61 medicinal products from 33 different pharmacological classes were subject to withdrawal due to cardiovascular adverse effects. Those most likely to cause cardiovascular toxicity were psychostimulants ($n=8$), analgesics ($n=5$), antiarrhythmics ($n=5$), antipsychotics ($n=4$) and vasodilators ($n=3$), with the remaining 36 drugs distributed among 28 classes, as demonstrated in Figure 2. There were 13 drugs which were both cardiovascular agents and were withdrawn due to cardiovascular toxicity, as shown in Table 2.

Discussion and conclusion

The benefits provided by a medication might come with associated risks to health and well-being. In all cases, benefits must outweigh risks by a significant margin. The ideal medication should combine; a high benefit-risk ratio, optimal treatment with the least number of medications and affordable cost of treatment.

TABLE 1. Cardiovascular drugs removed from the market due to adverse drug reactions between 1950–2017

Medicinal product	Class	Therapeutic indication	Reason for withdrawal	Total years in the market
Adenosine phosphate	Antiarrhythmic	Cardiac arrhythmia	Cardiovascular	43
Aliskiren	Antihypertensive	Hypertension	Angioedema	4
Amoproxan	Antianginal	Angina	Sensory systems, skin	1
Beclobrate	Antilipidemic	Hyperlipidemia	Hepatotoxicity	5
Benzarone	Thrombolytic	Varicose veins	Liver	28
Bepidil	Antiarrhythmic	Cardiac arrhythmia	Cardiovascular	23
Buflomedil	Vasodilator	Peripheral arterial occlusive disease	Neurotoxicity, cardiotoxicity	36
Cadralazine	Antihypertensive	Hypertension	Immunologic	3
Cerivastatin	Antilipidemic	Hyperlipidemia	Renal, musculoskeletal	4
Cinpezide	Vasodilator	Cerebrovascular disease	Hematologic	14
Clofibrate	Antilipidemic	Hyperlipidemia	Accelerated deaths	11
Cyclandelate	Vasodilator	Raynaud's disease	Not effective for use	9
Diethyl-aminoethoxyxestrol	Antianginal	Angina pectoris	Liver	6
Dilevalol	Antihypertensive	Hypertension	Liver	1
Dinoprostone*	Prostaglandin	Induction of labour	Fetal distress, uterine hypertonia	19
Dofetilide	Antiarrhythmic	Cardiac arrhythmia	Cardiovascular	5
Drotrecogin alfa (activated)	Antithrombotic	Sepsis	Insufficient evidence, bleeding risk	10
Encainide	Antiarrhythmic	Cardiac arrhythmia	Cardiovascular	6
Erythryl tetranitrate	Antihypertensive	Angina pectoris	Insufficient evidence, skin	43
Flosequinan	Vasodilator	Congestive heart failure	Death	1
Gallopamil	Antiarrhythmic	Cardiac arrhythmia	Not specified, cardiovascular	18
Gemfibrozil	Anticholesterol	Dyslipidemia	Negative benefit-to-harm balance	5
Guanethidine	Antihypertensive	Hypertension	Sensory systems	13
Hexestrol bis (beta- diethylaminoethyl ether)	Vasodilator	Hypertension	Hepatotoxicity	17
Hydrochlorothiazide + sotalol	Antihypertensive	Hypertension	Cardiovascular, drug interactions	16
Indoramin	Vasodilator	BPH, Hypertension	Cardiovascular	30
Isoprenaline	Cardiac stimulant	Bradycardia& heart block, asthma	Cardiovascular	43
Laropiprant /nicotinic acid	Antilipidemic	Facial Flushing	Higher frequency of non -fetal but serious side effects	0
Levarterenol	Vasopressor	Nonhemorrhagic shock	Nervous, Cardiovascular	69
Lysine amidotriazoate**	Radiography	Vascular diagnosis	Cardiovascular, hematologic, immunologic, urinary tract (safer alternatives)	20
Metipranolol	Antihypertensive	Hypertension	Sensory systems (uveitis)	5
Mibefradil	Antihypertensive	Hypertension	Drug interactions, musculoskeletal	1
Molsidomine	Antianginal	Angina pectoris	Tumorigenicity	13

TABLE 1 (CONT.). Cardiovascular drugs removed from the market due to adverse drug reactions between 1950–2017

Medicinal product	Class	Therapeutic indication	Reason for withdrawal	Total years in the market
Moxisylyte (thymoxamine uroalpha)	Antianginal	Benign prostatic hyperplasia	Liver	4
Muzolimine	Antihypertensive	Hypertension	Nervous system	4
Naftidrofuryl oxalate (IV)	Vasodilator	Intermittent claudication	Cardiovascular, immunologic, liver, urinary tract	18
Nifedipine (10 mg)	Antihypertensive	Hypertension	Cardiovascular	21
Pargyline	Antihypertensive	Hypertension	Interaction with tyramine	16
Pentosan polysulfate sodium	Antithrombotic	Cystitis, osteoarthritis	Hematologic, thrombocytopenia	29
Perhexiline lameate	Antianginal	Angina pectoris	Hypoglycemia, liver, musculoskeletal, nervous system	11
Phentolamine mesilate	Antihypertensive	Erectile dysfunction	Carcinogenicity	2
Polidexide	Antilipidemic	Hyperlipidemia	Oculomucocutaneous syndrome	3
Potassium canrenoate	Antihypertensive	Hypertension, ascites	Carcinogenic	18
Potassium nitrate	Antihypertensive	Hypertension	Tumorigenicity	80
Practolol	Antihypertensive	Hypertension	Gastrointestinal, sensory systems, skin	11
Prenylamine	Antianginal	Angina pectoris	Cardiovascular: multifactorial ventricular tachycardia	29
ProbucoI***	Antioxidant	Hyperlipidemia	Cardiovascular, Torsade de pointes	9
Pronethalol	Antihypertensive	Angina pectoris	Tumorigenicity	2
Sitaxentan sodium	Antihypertensive	Pulmonary arterial hypertension	Hepatotoxicity	4
Suloctidil	Vasodilator	Intermittent claudication	Liver, hepatotoxicity	10
Tienilic acid (ticrynafen)	Antihypertensive	Hypertension, kidney stones	Liver, urinary tract	4
Tocainide	Antiarrhythmic	Cardiac arrhythmia	Hematologic, agranulocytosis, aplastic anemia	5
Tripranol	Antilipidemic	Hyperlipidemia	Sensory systems, skin	3


*Dinoprostone is a prostaglandin which has a direct mechanism of action as a vasodilator; **Lysine amidotriazoate is a radioographic agent but it is used for vascular diagnosis; ***ProbucoI is an antioxidant which acts as an anti-hyperlipidemic drug; ****Two anticoagulants were excluded from this list as they are classified as haematological drugs.

It is noteworthy that some of the withdrawn drugs remained in the market for long periods. For instance, potassium nitrate despite its tumorigenic effects remained as an antihypertensive agent in the market for 80 years.

In contrast, synthetic Coumarin (anticoagulant) and Lapopirant/nicotinic acid (antilipidemic) were both withdrawn within a year of their launch, which is a testament to the improvements in the ADR report-

ing mechanisms and the awareness and acceptance of pharmacovigilance systems all over the world. In Turkey, withdrawals were done at the same time as EMA or FDA withdrawals, except sibutramine, which was withdrawn in Turkey due to the efforts of TUFAM a month ahead of EMA and 8 months ahead of FDA [8].

According to the WHO, at least 200 ADR reports are expected to be submitted per million persons annually



[9]. In the United States, ADR reports to FDA between the years 2006 and 2014 have shown a 2.7-fold increase [10]. These high rates of ADRs and the withdrawal of products even that had appeared as “good drugs” in the market for many years causes loss of confidence to both drugs and the health authorities [6]. Most drugs within the scope of this study were conventional drugs. On the other hand, the number of biotechnological drugs is increasing as both original products and biosimilar products due to expiration of biopharmaceutical patents. The number of ADRs on VigiBase Data has exceeded 12 million by 2015 [7, 11, 12], thus warranting increased awareness of pharmacovigilance.

Similarly, in Europe, EudraVigilance system, established by EMA, systematically works to encourage reporting of potential ADRs. In response to systematic works, number of submitted reports show an increasing trend and the number of reports submitted to EudraVigilance system exceeded 1 million in 2015 [13].

National Centres, such as TUFAM, also play a significant role in increasing public awareness of drug safety. The legal time limit of submitting traced ADR reports to TUFAM is restricted to 15 days. Annual number of ADR report submissions to TUFAM follow an increasing trend between 2006 and 2013, with the number of reports increasing by 8.2 times during this interval. However, the elevation of the number of ADR reports (2600 reports in 2013) is not high enough to reach the point expected from a population of 75 million according to a study [14]. Therefore, extensive collaboration between all partners of the pharmacovigilance system is necessary to ensure that a sufficient level of ADR reporting is achieved after marketing [3].

There are multiple intrinsic and extrinsic factors that can determine the patient’s response to any pharmaceutical agent. A meta-analysis by Hakkarainen et al. suggested that 45–52% of ADRs are preventable [15]. One significant intrinsic factor is the genetic make-up of the patient. As the genetic make-up of each person is unique, the emerging field of pharmacogenomics can greatly facilitate the tailoring of a patient-specific dose regimen and aid in the reduction of ADRs occurring. As case-in-point, a recent study by He, Shi and Qui showed




TABLE 2. Cardiovascular drugs withdrawn due to their adverse effects on the cardiovascular system

Medicinal Product	Class	Reason for withdrawal
Prenylamine	Antianginal	Cardiovascular: multifactorial ventricular tachycardia
Adenosine phosphate	Antiarrhythmic	Cardiovascular
Bepidil	Antiarrhythmic	Cardiovascular
Dofetilide	Antiarrhythmic	Cardiovascular
Encainide	Antiarrhythmic	Cardiovascular
Gallopamil	Antiarrhythmic	not specified, Cardiovascular
Hydrochlorothiazide+sotalol	Antihypertensive	Cardiovascular, Drug interactions
Nifedipine (10mg)	Antihypertensive	Cardiovascular
Isoprenaline	Cardiac stimulant	Cardiovascular
Buflomedil	Vasodilator	Neurotoxicity, cardiotoxicity
Indoramin	Vasodilator	Cardiovascular
Naftidrofuryl oxalate (IV)	Vasodilator	Cardiovascular, immunologic, liver, urinary tract
Levarterenol	Vasopressor	Nervous, cardiovascular

a correlation between a functional polymorphism in the CYP3A4 gene and an increased risk of coronary heart disease in the study population [16].

The main target of both pharmacogenomics and pharmacovigilance is to understand the heterogeneity and the structure of the drug efficacy and safety distribution signals among the population. Although these two disciplines are synergistic conceptually and practically, these disciplines do not have a sensible convergence up to now [17].

Current implementation of pre-licensing Phase III trials involves the participation of 500 to 10,000 individuals, followed by the full licensing of the drug for the market. Post-marketing studies, which succeed the launch of the drug, are optional under the current regime. In light of the pharmacovigilance concept, it has become necessary that drugs undergoing Phase III trials with at least 3,000 individuals should only obtain a conditional approval, followed by compulsory post-marketing studies involving at least 30,000 individuals by taking ADR reports into consideration for newly discovered drug molecules, only after which the full license should be issued. Building on these considerations health problems caused by ADRs can be highly mitigated [18, 19].

In the light of the above information, the existing drug safety procedures should be widely reconsidered. In conclusion, collaboration between the participants of pharmacovigilance system is necessary to develop and

maintain an effective system for detecting post-marketing safety risks to protect public health.

Conflict of Interest: Authors declare no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship contributions: Concept – S. S.; Design – K. K.; Supervision – S. S.; S. S.; Materials – K. K.; F. B. A.; Data Collection and/or processing – K. K.; S. S.; F. B. A.; Analysis and/or interpretation – K. K., S. S.; Literature search – K. K.; S. S.; F. B. A.; S. S.; Writing – K. K.; S. S.; F. B. A.; S. S.; Critical Review – S. S.; S.S.

REFERENCES

- Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients A Meta-analysis of Prospective Studies. *JAMA*. 1998;279(15):1200-1205.
- UMC | Members. Who-umc.org. Retrieved 27 May 2017, from <https://www.who-umc.org/global-pharmacovigilance/members/>
- Uppsala: the Uppsala Monitoring Center, Uppsala Reports October 2005. 1st ed. (2005) p.5. Available at: <http://www.who-umc.org/graphics/24369.pdf>
- Onakpoya, I., Heneghan, C. and Aronson, J. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. *BMC Medicine*, (2016) 14(1).
- Sultana, J., Cutroneo, P., & Trifirò, G. Clinical and economic burden of adverse drug reactions. *Journal Of Pharmacology And Pharmacotherapeutics*, (2013) 4(5), 73.
- Giacomini KM, Ronald MK, Roden MD, et al. When good drugs go bad. *Nature* 2007; 446: 975-7
- Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database*

- Syst Rev 2011; 16 (2): CD008794
8. T.C. Sağlık Bakanlığı Pepper Time Kapsül (Biber hâpı) hakkında, Sağlık Bakanlığı İlaç ve Eczacılık Genel Müdürlüğü (05.08.2010 tarih ve B.10.0.İEG.0.11.00.01-330.06 sayılı yazısı).
 9. WHO, Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre: 5. Special Issues In Reporting: 5.3 Under-reporting (2000). Available at: <http://apps.who.int/medicinedocs/en/d/Jh2934e/6.3.html>
 10. Fda.gov, Reports Received and Reports Entered into FAERS by Year, (2015). Available at: <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm>
 11. Prinz JC. Biologics. New drugs, new adverse reactions. *Hautarzt* 2010; 61 (8): 668-75
 12. Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. *J Dtsch Dermatol Ges* 2010; 8 (6): 411-26
 13. EMA, 2015 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission (2016). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/03/WC500203705.pdf
 14. Ozcan, G., Aykac, E., Kasap, Y., Nemutlu, N., Sen, E., & Aydinkara-haliloglu, N. Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation (2016). *Drugs - Real World Outcomes*, 3(1), 33-43.
 15. Hakkarainen, K. M., Hedna, K., Petzold, M., & Hägg, S. Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis. *PLoS ONE* (2012), 7(3), e33236.
 16. He BX, Shi L, Qiu J, et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. *Basic Clin Pharmacol Toxicol* 2011; 108 (3): 208-13).
 17. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. *JAMA* 2001; 286: 2270-9.
 18. Strom BL. How the US Drug Safety System Should Be Changed. *JAMA*. 2006;295(17):2072–2075.
 19. Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun J, Krumholz HM, Ross JS. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. *JAMA*. 2017;317(18):1854–1863.